Van Oijen AH et al. |
Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930892
|
Hurenkamp GJ et al. |
Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930901
|
Lai KC et al. |
Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930902
|
Cardenas VM et al. |
Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16393310
|
Gatta L et al. |
A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963079
|
Wong BC et al. |
Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11380322
|
Meier R et al. |
Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11380323
|
al-Assi MT et al. |
Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. |
1994 |
Aliment. Pharmacol. Ther. |
pmid:7986970
|
Miehlke S et al. |
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16842467
|
Neri M et al. |
Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. |
1994 |
Aliment. Pharmacol. Ther. |
pmid:7986974
|
Spinzi G et al. |
Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9146769
|
Okudaira K et al. |
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15710002
|
Zullo A et al. |
High eradication rates of Helicobacter pylori with a new sequential treatment. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12641522
|
Lane JA et al. |
Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21366634
|
Fock KM et al. |
Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10651664
|
Wong BC et al. |
One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207516
|
Lamouliatte H et al. |
Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10571611
|
Fischbach LA et al. |
Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15569109
|
Bazzoli F et al. |
Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11856090
|
Kim JS et al. |
Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860410
|
Poon SK et al. |
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860412
|
Peitz U et al. |
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860415
|
Qasim A and O'Morain CA |
Review article: treatment of Helicobacter pylori infection and factors influencing eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11849124
|
Sheu BS et al. |
Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12197847
|
Grimley CE et al. |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383520
|
Spadaccini A et al. |
Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9798805
|
Houben MH et al. |
Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383522
|
Bortolotti M et al. |
Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9798808
|
Calvet X et al. |
A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10792124
|
John Albert M et al. |
High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:17059517
|
Furuta T et al. |
Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17697203
|
Malfertheiner P et al. |
Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12752349
|
Veldhuyzen Van Zanten S et al. |
One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121908
|
Isomoto H et al. |
5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121910
|
Canducci F et al. |
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121911
|
Toracchio S et al. |
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121913
|
Kim YS et al. |
Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21923713
|
Kawabata H et al. |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12534411
|
Gisbert JP et al. |
Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11012477
|
Catalano F et al. |
Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11012478
|
Gomollón F et al. |
Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11012479
|
Graham DY et al. |
Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102946
|
Zanten SJ et al. |
The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102960
|
Van der Wouden EJ et al. |
The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102961
|
Wong BC et al. |
Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102962
|
Xiao SD et al. |
High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102963
|
Nista EC et al. |
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12969089
|
Feydt-Schmidt A et al. |
Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12452940
|
Isomoto H et al. |
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12848631
|
Nista EC et al. |
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15569121
|